MITUniversities

Allied for Essential Medicines

PIH/David WaltonPIH/David WaltonPIH/David WaltonPIH/David Walton

• You bring kindness, and your kindness is good. But it will not cure this AIDS.

• I know there is medicine in your country for people like you. But why not here, for people like me?

Pharmaceutical industry expendituresWorldwide, 1996-2005

12% R&D

25% Profits

30% Operational and material costs

32% Marketing and administration

Flickr/MikeBlythFlickr/MikeBlythFlickr/MikeBlythFlickr/MikeBlyth

Drs. Prusoff and Lin at Yale discovered that d4t (stavudine, Zerit) is

active against HIV. D4t became a key first-line antiretroviral.

Because Yale licensed d4t exclusively to Bristol Myers Squibb, the

company set a monopoly price (too high for poor patients)

Impact of Generic Competition:

Uganda

Magnum Photos/Francesco ZizolaMagnum Photos/Francesco ZizolaMagnum Photos/Francesco ZizolaMagnum Photos/Francesco Zizola

In South Africa, MSF and the Treatment Action Campaign bought low-price,

generic d4t to save the lives of the HIV+ poor.

The generic d4t was technically illegal, because it infringed on Bristol Myers

Squibb’s patent on d4t in South Africa.

Before ARV therapy After six months on ARV therapyPIH/David WaltonPIH/David WaltonPIH/David WaltonPIH/David Walton

Antiretroviral treatment can literally bring a dying patient back

to life. Here, Joseph in Haiti, treated by Partners in Health.

Bristol Myers Squibb launched a lawsuit for patent infringement against the

South African generic company, essentially asserting that it is acceptable to die

of a treatable infection so long as you are poor enough.

“The Scientist’s Story”

““I once helped create a drug that could enable millions of I once helped create a drug that could enable millions of

people to lead better and longer lives…More recently, it people to lead better and longer lives…More recently, it

became apparent that the drug Dr. Lin and I had developed became apparent that the drug Dr. Lin and I had developed

was not reaching millions of desperately suffering people was not reaching millions of desperately suffering people

because they lacked the money to purchase it.”because they lacked the money to purchase it.”

NYTimes Editorial: March 19, 2001 By William Prusoff.

Role of Academic Research

Academic patents in 1 in every 5 of the most innovative Rx (FDA priority review)

Academic patents in 1 in every 4 HIV Rx.

In 44% of cases, universities filed for patent protection in developing world.

Sampat, Am J. Pub. H., 2009

PhRMA Sales by Geographic Area

Gener-X

Patent

GlobalAccess

Licensing

The New “Scientist’s Story”The New “Scientist’s Story”• Dr. Kishor M. Wasan

Meeting with Harvard’s PresidentJust prior to SPS (October 2009)

The Statement of Principles and Strategies for

Equitable Dissemination of Medical

Technologies (SPS) is Born

Yale

Provost

agrees to

articulate

policies

Discuss Stakeholder Meeting,

Committee on Global Access

Licensing with Dean of Public

Health

Crimson

op-ed

exchange

Faculty outreach for Working

Group on Licensing

First meeting

with OTD,

friendly

Petition to

Provost

Yale

monthly

OTD

meetings

Provost and

TTO Head

reveal plans

to develop

multi-

university

agreement

Meeting

with OTD

and

CEOs,

unfriendly

Multi-

University

Roundtable

Say Yes

To Drugs

Campaign

SPS

Launched

Meeting

with

Harvard

President

Current Signatories

Institution Signing DateAssociation of University Technology Managers 11/9/2009Boston Univ 11/9/2009Brown Univ 11/9/2009Harvard Univ 11/9/2009Univ of Pennsylvania 11/9/2009Yale Univ 11/9/2009Oregon Health & Science University 11/9/2009National Institutes of Health 11/10/2009University of Illinois Chicago 11/10/2009University of Illinois Urbana-Champaign 11/11/2009Centers for Disease Control and Prevention 11/12/2009University of Vermont and State Agricultural College 11/19/2009Duke University and Duke Medicine 12/1/2009University of British Columbia 1/10/2010Bilkent University 1/27/2010El Colegio de México 1/27/2010New York University 2/4/2010Tecnologico de Monterrey 2/13/2010Jawaharlal Nehru University 2/18/2010Najit Technologies, Inc. 3/4/2010Brigham & Women's Hospital 3/15/2010Florida State University 3/29/2010Massachusetts General Hospital 3/29/2010

Mission Statement

The mission of MIT is to advance knowledge and educate students

in science, technology, and other areas of scholarship that will

best serve the nation and the world in the 21st century.

The Institute is committed to generating, disseminating, and

preserving knowledge, and to working with others to bring

this knowledge to bear on the world's great challenges. MIT

is dedicated to providing its students with an education that

combines rigorous academic study and the excitement of

discovery with the support and intellectual stimulation of a

diverse campus community. We seek to develop in each member

of the MIT community the ability and passion to work wisely,

creatively, and effectively for the betterment of humankind.

Our Vision

Universities and publicly funded research institutions will be part of the

solution to the access to medicines crisis by promoting medical

innovation in the public interest and ensuring that all people regardless

of income have access to essential medicines and other health-related

technologies.

Our Mission

As a private non-profit organization rooted in a movement of university

students, UAEM aims to

- promote access to medicines for people in developing countries by

changing norms and practices around university patenting and licensing

- ensure that university medical research meets the needs of the majority

of the world’s population

- empower students to respond to the access and innovation crisis